City of Hope Publications
City of Hope’s John Zaia, M.D., will lead the development of the phase 1 clinical trial for glioblastoma patients, which would genetically alter blood stem cells to better tolerate chemotherapy.
According to a new paper in Stem Cells Translational Medicine, the authors identify the role of a nurse qualified in both patient care and research protocols, the so-called “hybrid nurse” — a homegrown City of Hope innovation — as an important component of their success in the development of the Alpha Clinic.
Dan Rojas, 31, who has been living with HIV since 2011, is one of a handful of brave patients participating in a groundbreaking study at City of Hope that seeks a cure for AIDS.
When Christina Joseph, B.S.N., R.N., was in nursing school, a close teacher and mentor was diagnosed with cancer. “I took that as a sign,” said the Southern California native. “So I went into oncology nursing.”
Patients who have benefited from stem cell therapies funded by CIRM were the focus of the second symposium of the Alpha Stem Cell Clinics Network.
The stories of patients who have benefited from stem cell therapies funded by the California Institute for Regenerative Medicine (CIRM) were the focus of the second symposium of the institute’s Alpha Stem Cell Clinics Network.
Linda Malkas, Ph.D., who holds the M.T. & B.A. Ahmadinia Professorship in Molecular Oncology, has been appointed to the governing board of CIRM, the state’s stem cell agency.
The stories of patients who have benefited from stem cell therapies funded by CIRM will be highlighted at the second symposium of the institute’s Alpha Stem Cell Clinics Network at City of Hope.
City of Hope case study published in the New England Journal of Medicine reported treatment with reengineered CAR T cells dramatically improved quality of life for patient with recurrent glioblastoma.
Aaron Kim is the first HIV patient treated as part of a new City of Hope clinical trial that will determine if a patient’s own genetically engineered bone marrow cells can safely be used to treat HIV.
“We could see a functional cure for HIV in the next 5-10 years,” predicts John Zaia, M.D., a world-renowned genetic researcher and Director of the Center for Gene Therapy at City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute.
A gliobastoma patient has become the first person to be treated by City of Hope's new Alpha Clinic for Cell Therapy and Innovation (ACT-I), heralding a potential breakthrough in the treatment for brain tumors and in the use of stem cells.
A brain tumor patient is the first to be treated by City of Hope’s Alpha Clinic for Cell Therapy and Innovation, part of the state’s Alpha Clinics network, created to speed the development and delivery of stem cell therapies to patients who desperately need them.
Now, as City of Hope officially opens the Alpha Clinic for Cell Therapy and Innovation, patients battling cancer and other life-threatening diseases have another option: stem cell-based therapy.
The promise of stem cell therapy has long been studied in laboratories. Now, as medicine enters an era in which this therapy will be increasingly available to patients, the nurses who help deliver it will be in the spotlight.
The new stem cell therapy clinic is expected to revolutionize not just the treatment of cancer, but also AIDS and other life-threatening diseases.
Grant will enable scientists to adapt current cell culture techniques to a more scalable and controllable system that reflects GMP. Innovative platform will allow larger scale production and storage of stem cells.
City of Hope joined other leaders in stem cell research to celebrate 10 years since voters approved funding for the California Institute for Regenerative Medicine, or CIRM.
Physicians and scientists at the Hematologic Malignancies and Stem Cell Transplantation Institute are using T cell therapy against blood cancers and other diseases.
Identifying cures for currently incurable diseases and providing patients safe, fast, and potentially life-saving treatments is the focus of City of Hope’s new Alpha Clinic for Cell Therapy and Innovation (ACT-I).